Skip to content

"COMPARISON OF TREATMENT RESPONSE TO TOPICAL PROPOLIS VERSUS STANDARD IN THE MANAGEMENT OF ORAL CANCEROUS DISORDERS AND ROLE 0F ALPHA ENOLASE(ENO1) AND GALECTIN 9(GAL9) AS POTENTIAL MARKERS FOR DETECTING ORAL CANCEROUS DISORDERS AND ORAL CANCER : A RANDOMIZED CONTROL CLINICAL TRIAL"

"COMPARISON OF TREATMENT RESPONSE TO TOPICAL PROPOLIS FORTIFIED WITH VITAMINS VERSUS TRIAMCINOLONE ACETONIDE IN THE MANAGEMENT OF ORAL POTENTIALLY MALIGNANT DISORDERS AND ROLE OF ALPHA ENOLASE(ENO1) AND GALECTIN 9(GAL9) AS CRITICAL REGULATORS FOR ORAL POTENTIALLY MALIGNANT DISORDERS AND ORAL SQUAMOUS CELL CARCINOMA: A RANDOMIZED CONTROL CLINICAL TRIAL" - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/059696
Enrollment
120
Registered
2023-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis

Interventions

Intervention1: Propolis: Topical application of Propolis thrice daily for 6 months.Follow up at regular interval of 4 weeks up to 6 months. Control Intervention1: Triamcinalone acetonide: Topical app

Sponsors

Maulana Azad Institute of Dental Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically & histopathologically proven cases of OSMF and OLP and OSCC Any subject of age group18 to 50 years. Both males and females. A positive history of chewing areca nut or one of its commercial preparation, difficulty in swallowing and chewing, and burning sensation on eating spicy foods.(osmf) Restricted mouth opening and changes in the oral mucous membrane including the presence of palpable vertical fibrous bands, stiffness and blanching.(osmf)

Exclusion criteria

Exclusion criteria: Subjects with mouth opening less than 15 mm. Subjects with systemic diseases, immunocompromised patients and patients who are taking medications which may effect the result of the study. Pregnant and nursing women. Subjects who are known allergic to honey bees or bee products. Those patients who are not willing to participate in study.

Design outcomes

Primary

MeasureTime frame
Mouth Opening, Tongue Protrusion, Cheek flexibility, VAS score,pain score.Timepoint: 4 weeks up to 6 months

Secondary

MeasureTime frame
To evaluate whether topical propolis can be used as an alternative to topical triamcinolone acetonide for treating OPMDs . Timepoint: 4 weeks up to 6 months

Countries

India

Contacts

Public ContactDR SUJOY GHOSH

MAULANA AZAD INSTITUTE OF DENTAL SCIENCES

DRSUJOYGHOSH@GMAIL.COM95829111387

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026